<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28435">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01917916</url>
  </required_header>
  <id_info>
    <org_study_id>1293.8</org_study_id>
    <nct_id>NCT01917916</nct_id>
  </id_info>
  <brief_title>Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655064 (Buffer Solution for Injection) in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebocontrolled Within Dose Groups, Clinical Phase I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>South Korea: Ministry of Food and Drug Safety (MFDS)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 655064 after single rising
      doses in healthy Asian male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of patients with drug-related adverse events</measure>
    <time_frame>up to 91 days post dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 70 days post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity</measure>
    <time_frame>up to 70 days post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz</measure>
    <time_frame>up to 70 days post dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 655064 dose group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject to receive BI 655064 dose group 1 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to BI 655064 dose group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subject to receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 655064 dose group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject to receive BI 655064 dose group 2 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to BI 655064 dose group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subject to receive a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 655064 dose group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject to receive BI 655064 dose group 4 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to BI 655064 dose group 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject to receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 655064 dose group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject to receive BI 655064 dose group 3 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to BI 655064 dose group 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject to receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo to BI 655064 dose group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655064</intervention_name>
    <arm_group_label>BI 655064 dose group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655064</intervention_name>
    <arm_group_label>BI 655064 dose group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655064</intervention_name>
    <arm_group_label>BI 655064 dose group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo to BI 655064 dose group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 655064</intervention_name>
    <arm_group_label>BI 655064 dose group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo to BI 655064 dose group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo to BI 655064 dose group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy males based upon a complete medical history, including the physical
             examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests

          -  Chinese ethnicity, Japanese ethnicity according to the following criteria. Japanese:
             born in Japan, have lived outside of Japan &lt;10 years, and have parents and
             grandparents who were all born in Japan. Chinese: ethnic Chinese, born in China or
             ethnic Chinese born outside of China, and a descendent of 4 ethnic Chinese
             grandparents who were all born in China

          -  Age within the range of 20 to 45 years inclusive

          -  Body mass index within the range of 18.5 and 25 kg/m2 inclusive

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation.

        Exclusion criteria:

          -  Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          -  Any disease or clinically relevant abnormality in laboratory parameters which,
             according to the investigator, might compromise the safety of the subject or
             interfere with the subjects participation in the trial or compromise the trial
             objectives

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells or blackouts.

          -  Chronic or relevant acute infections
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1293.8.8101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sumida-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1293.8.8201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>August 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
